Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) has received an average recommendation of “Moderate Buy” from the five ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $14.75.
Several research analysts recently commented on CLBT shares. Weiss Ratings raised Cellebrite DI from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday. JPMorgan Chase & Co. cut their target price on shares of Cellebrite DI from $16.00 to $15.00 and set an “overweight” rating on the stock in a research note on Friday. DA Davidson reaffirmed a “buy” rating and issued a $15.00 target price on shares of Cellebrite DI in a report on Tuesday, September 15th. Lake Street Capital decreased their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Finally, Needham & Company LLC boosted their price target on shares of Cellebrite DI from $12.50 to $14.00 and gave the stock a “buy” rating in a report on Thursday, November 12th.
View Our Latest Stock Report on Cellebrite DI
Insider Buying and Selling
In related news, insider Thomas E. Hogan sold 25,299 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $11.29, for a total value of $285,625.71. Following the sale, the insider owned 765,249 shares in the company, valued at $8,639,661.21. This represents a 3.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CMO David Gee sold 4,323 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $11.36, for a total transaction of $49,109.28. Following the transaction, the chief marketing officer directly owned 135,281 shares of the company’s stock, valued at approximately $1,536,792.16. This trade represents a 3.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 57,143 shares of company stock worth $645,005. Insiders own 5.70% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the business. Elevation Wealth Partners LLC purchased a new stake in Cellebrite DI during the 2nd quarter worth approximately $44,000. PNC Financial Services Group Inc. raised its position in shares of Cellebrite DI by 59.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 7,456 shares of the company’s stock valued at $103,000 after purchasing an additional 2,785 shares in the last quarter. Pacer Advisors Inc. boosted its stake in shares of Cellebrite DI by 91.1% during the 1st quarter. Pacer Advisors Inc. now owns 7,607 shares of the company’s stock valued at $105,000 after buying an additional 3,626 shares during the last quarter. Ground Swell Capital LLC purchased a new position in shares of Cellebrite DI during the 3rd quarter valued at approximately $128,000. Finally, Quantinno Capital Management LP purchased a new position in shares of Cellebrite DI during the 1st quarter valued at approximately $150,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.
Cellebrite DI Stock Performance
CLBT stock opened at $11.12 on Friday. Cellebrite DI has a one year low of $9.58 and a one year high of $19.39. The firm has a market cap of $2.78 billion, a PE ratio of 33.00, a PEG ratio of 1.67 and a beta of 1.06. The firm’s 50 day moving average price is $11.59 and its 200-day moving average price is $13.19.
Cellebrite DI Company Profile
Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.
See Also
- Five stocks we like better than Cellebrite DI
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.
